The race for med-tech companies to get a bioabsorbable stent (BVS) on the U.S. market for coronary intervention procedures is quickly heating up. Abbott Vascular (Santa Clara, Calif.), a division of Abbott (NYSE: ABT) (Abbott Park, Ill.), is pulling away from other competitors in the space and has developed a BVS that can be fully dissolved within the body.